Combination therapy of resistant warts in a patient with AIDS.
BACKGROUND
An AIDS patient on anti-HIV therapy consisting of two reverse transcriptase inhibitors had a low CD4+ lymphocyte count, a high HIV viral RNA load, and facial warts that were resistant to ablative therapy.


OBJECTIVE
To find a regimen to treat resistant warts in an AIDS patient with a depressed CD4 count and high HIV viral load.


METHODS
A protease inhibitor was added to his regimen and he was treated with ablative therapy using a 585 nm flashlamp-pumped pulsed dye laser (FPPDL).


RESULTS
Observed resolution of the warts one month later, with no recurrence at seven-month follow-up.


CONCLUSIONS
Treatment of resistant warts in patients with AIDS may be enhanced by triple-drug therapy which includes a protease inhibitor, used in combination with ablative therapy, such as the FPPDL.
Roark
T R
TR
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas 75235-9069, USA.
Pandya
A G
AG
D017088:AIDS-Related Opportunistic Infections / Q000628:therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D053685:Laser Therapy; D008047:Lip Diseases / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014860:Warts / Q000628:therapy*
D019380:Anti-HIV Agents